RTH258 is NVS’ next-generation anti-VEGF compound that may eventually be co-formulated with OPHT’s Fovista.
In the above trial, two doses of RTH258 are being tested. The primary endpoint is visual acuity at 48 weeks. Approximately 1000 patients are to be enrolled, randomized 1:1:1. Expected completion Jun 2018.
H/t ‘jq1234’.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.